HydraMed Review
Appears to have shut downHydraMed is closed and is not taking new patients. It charged from $179 a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
HydraMed is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
Last published price before it closed: $179/mo. No longer offered.
See our top-rated GLP-1 providers →HydraMed is a nationwide telehealth platform selling compounded semaglutide and tirzepatide plus a broader peptide menu that includes PT-141, GHK-Cu, and NAD+ in injection, nasal, and topical forms. Monthly pricing is all-inclusive, covering prescription and supplies, with free shipping and a quick medical questionnaire at intake. Compounding is performed at a US FDA-registered pharmacy. It also runs mobile IV services in CO, FL, TN, and WY.
Vetted alternatives to HydraMed
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
AgelessRx
Best for: microdosed compounded GLP-1s from a longevity clinic, or brand Wegovy at manufacturer pricing plus monitoring
Editorial score · methodology
HydraMed at a glance
- Status
- Closed: not taking new patients
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Last published price
- $179/mo
- What it included
- Medication · Consult · Shipping · Coaching
- Availability
- 11 states
- FDA status
- 1 FDA warning letter (details below)
How HydraMed scores
HydraMed has closed. These scores describe what it published when we last checked it, before it stopped taking patients.
Six columns, each one computed from something HydraMed published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
5.8/10$179/month is 10% below the $199 median for compounded semaglutide across the sellers we compare.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
5.0/10Where this seller first shows a price is not known, so sign-up is held at the midpoint.
Trust & Safety15%
3.0/10The FDA has issued it a warning letter. No pharmacy is named for its prescriptions. There is no confirmed price before the medical intake. It lists the states it serves.
Accessibility10%
3.8/10Serves 11 of 50 states.
Support10%
8.5/10The price covers the medication, clinician visits, shipping and coaching.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on HydraMed
Last checked June 2026- Checked the listed price across 3 dose or plan tiers
- Checked state coverage: 11 states
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for HydraMed
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
Medications HydraMed listed
HydraMed listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Prices it published before closing
Prices re-verified
In its favor
- Semaglutide cost $179 a month, 10% below the $199 median for compounded semaglutide across the sellers we compare
- The monthly price included the medication, clinician visits, shipping and coaching
Against it
- Tirzepatide cost $319 a month, 19% above the $269 median for compounded tirzepatide across the sellers we compare
- Served only 11 states
- The FDA has issued HydraMed a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
HydraMed is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.
What HydraMed charged
HydraMed charged $179/month.
- Compounded semaglutide (0.25 mg): $179/month
- Compounded semaglutide (1 mg): $249/month
- Compounded tirzepatide: $319/month
For compounded semaglutide, the median across the sellers we compare is $199/month, so HydraMed's $179 is genuinely below the middle, not just advertised that way.
Bodybuilding Health+, at about $179/month, is the closest like-for-like alternative we review.
What HydraMed dispensed
HydraMed prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
Safety and disclosure
HydraMed told buyers the 11 states it served. It also offered coaching as part of the plan. The FDA has issued HydraMed a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Our read
HydraMed is no longer taking new patients, so the choice is among the sellers that are still open. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.
The Bottom Line
HydraMed is closed and is not taking new patients. It charged from $179 a month.
Where HydraMed is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
- If your state is outside the area this one covers, consider Embody.
If none of these fits, our guide to alternatives to HydraMed sets more sellers in the same category beside HydraMed on price, states and what the price includes.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
HydraMed has an FDA warning letter on record, dated June 8, 2026
This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this HydraMed review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of June 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.